NovoMix 30 Penfill

Manufacturer: Novo Nordisk

Pharmaceutical name: Insulin Aspart

Pack: 1 pack (5 cartridges x 3ml (100 iu/ml))

NovoMix 30 Penfill (prefilled pens) contains 30% soluble (rapid-acting) Insulin Aspart and 70% protamine-crystallised (intermediate-acting) insulin aspart. It is used for the treatment of diabetes and is suitable for individuals aged 10 years and older.

 

NovoMix 30 Penfill is administered via injection into the skin of the abdominal area (stomach) or thigh. It can also be injected in the deltoid (shoulder) or gluteal (buttock) areas if preferred. Regular testing of blood glucose levels is necessary to determine the lowest effective dose. NovoMix is typically administered right before a meal but can be taken after a meal if needed. The usual dosage ranges from 0.5 to 1.0 units per kilogram of body weight per day.

 

In the case of type 2 diabetes, NovoMix 30 Penfill may be used alone or in conjunction with metformin (another diabetes medication). It can also be combined with other oral antidiabetes medications; however, it should only be paired with pioglitazone if the doctor has assessed the patient’s risk of experiencing fluid-related side effects. For additional details, consult the summary of product characteristics (also found in the EPAR).

 

Patients can self-administer NovoMix 30 Penfill after completing the necessary training.

 

Diabetes is a condition where the body lacks sufficient insulin to regulate blood glucose levels. NovoMix 30 Penfill acts as a replacement insulin that closely resembles the insulin produced by the pancreas.

 

The active ingredient in NovoMix 30 Penfill, insulin aspart, is created using recombinant DNA technology, which involves a yeast that has been modified to produce insulin aspart.

 

Insulin aspart differs slightly from human insulin. This slight modification allows it to be absorbed more rapidly by the body than human insulin, enabling it to take effect sooner. NovoMix 30 Penfill comprises insulin aspart in two forms: the soluble form that acts within 10 minutes post-injection and the crystallised form that is absorbed more gradually throughout the day. This replacement insulin functions similarly to naturally occurring insulin, facilitating the entry of glucose into cells from the bloodstream. By managing blood glucose levels, the symptoms and complications of diabetes are alleviated.

 

In studies, NovoMix 30 Penfill produced nearly identical outcomes to biphasic human insulin 30. Furthermore, adding NovoMix 30 to other antidiabetes medications led to improved blood glucose control compared to the use of the other medications alone.

 

The most frequently observed side effect of NovoMix 30 Penfill (occurring in more than 1 in 10 patients) is hypoglycaemia (low blood glucose levels). For a comprehensive list of all side effects associated with NovoMix, refer to the Package Leaflet.

 

NovoMix 30 Penfill should not be administered to individuals who may be allergic to insulin aspart or any of its other components. The doses of NovoMix may also need adjustment when used alongside other medications that can influence blood glucose levels. For a complete list of these medications, consult the Package Leaflet.